Sphingosine-1-phosphate: characterization of its inhibition of platelet aggregation.
In this study, the ability of sphingosine-1-phosphate (S1P) to modulate platelet aggregation induced by other agents in platelet-rich plasma (PRP) was investigated. S1P alone did not stimulate platelet aggregation in PRP. S1P inhibited the platelet aggregation induced by the TRAP peptide (6.75 microM), noradrenaline (NA; 12.5 microM) and the Ca2+ ionophore (5.0-9.5 microM). S1P also increased the response time of platelets to arachidonic acid (AA), but decreased the response time to PMA. S1P displayed a dual effect on sodium fluoride (NaF)-induced platelet aggregation and had no effect on the aggregation induced by ADP or lysophosphatidic acid (LPA). Furthermore, S1P blocked the synergistic interaction of oleyol-lysophosphatidic acid (O-LPA) with the TRAP peptide or noradrenaline, while the synergistic interaction of O-LPA with ADP remained largely unaffected.
Nugent
D
D
Department of Cancer Biology, Cleveland Clinic Foundation, OH 44195, USA.
Xu
Y
Y
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008246:Lysophospholipids / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010712:Phosphatidic Acids / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology; D018179:Receptors, Thrombin; D012969:Sodium Fluoride / Q000494:pharmacology; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology
D008246:Lysophospholipids; D010712:Phosphatidic Acids; D010975:Platelet Aggregation Inhibitors; D011506:Proteins; D018179:Receptors, Thrombin; C060506:sphingosine 1-phosphate; D000001:Calcimycin; D000244:Adenosine Diphosphate; D012969:Sodium Fluoride; D013110:Sphingosine; D009638:Norepinephrine